As pharmacy leaders balance daily clinical demands with long-term innovation, staying informed on emerging therapies and innovations is more critical than ever. Pharmacogenomics, biosimilars, and cell and gene therapies are advancing rapidly—and their clinical, financial, and operational implications are being felt across IDNs. These innovative topics are not only transforming treatment pathways, but also challenging formulary decisions, infrastructure readiness, and care delivery models.

Join industry thought leaders as they provide an update on some of the most influential topics in pharmacy today and outline actionable strategies for implementing or optimizing your organization’s current processes.

Learning Objectives:
1. Specify how pharmacogenomic insights are being applied within clinical decision-making across your organization.
2. Compare recent market trends in biosimilars and their impact on formulary decisions.
3. Outline the current state of cell and gene therapy adoption and the operational requirements needed for implementation.
4. Analyze the implications of these evolving pharmacy topics on your pharmacy.

As regulatory requirements tighten and operational complexities increase, many IDN pharmacies are turning to centralized sterile compounding centers to enhance quality control, improve efficiency, and ensure compliance. These centers offer opportunities to standardize practices, reduce site-level burden, and create scalable models for sterile medication preparation—but require significant planning, oversight, and investment.

Join pharmacy experts as they share their experiences implementing and managing centralized compounding centers and explore the opportunities and challenges that this could pose to your organization.

Learning Objectives:
1. Describe the strategic role of centralized sterile compounding centers within an IDN.
2. Evaluate the clinical, operational, and regulatory considerations involved in developing and maintaining centralized sterile compounding centers.
3. Identify key benefits and challenges associated with shifting from site-level to centralized sterile compounding.
4. Formulate an implementation roadmap for organizations considering a transition to centralized compounding models.

With specialty medications continuing to drive significant pharmacy spend, clinical teams are playing a more active role in addressing all drug costs – beyond financial negotiations and payer strategies. From optimizing prescribing practices and enhancing prior authorization workflows to developing evidence-based treatment pathways, pharmacists are uniquely positioned to influence cost through clinical decision-making.

Join industry thought leaders as they examine how pharmacy leaders are combatting high drug costs with a clinical focus, rather than financial. 

Learning Objectives:
1. Identify clinical practices that influence the appropriate and cost-conscious use of specialty medications.
2. Differentiate between financial interventions and clinically driven approaches to managing drug utilization.
3. Evaluate the role of pharmacists in creating evidence-based protocols and care pathways that optimize both outcomes and affordability.
4. Construct strategies for integrating clinical oversight into specialty pharmacy management to improve value.